Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $346,046 were sold by Burnett Patrick on Jul 10 ’25. At $15.05 per share, Burnett Patrick sold 23,000 shares. The insider’s holdings dropped to 115,468 shares worth approximately $1.79 million following the completion of this transaction.
Also, Burnett Patrick sold 5,750 shares, netting a total of over 86,654 in proceeds. Following the sale of shares at $15.07 each, the insider now holds 115,468 shares.
Before that, Burnett Patrick had added 5,750 shares to its account. In a trade valued at $86,654, the Officer bought Arcutis Biotherapeutics Inc shares for $15.07 each.
As published in their initiating research note from H.C. Wainwright on December 30, 2024, Arcutis Biotherapeutics Inc [ARQT] has been a Buy and the price target has been revised to $19. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in late August. As of January 03, 2024, Mizuho has increased its “Neutral” rating to a “Buy” for ARQT. Earlier on October 26, 2023, Mizuho downgraded its rating. Their new recommendation was “a Neutral” for ARQT stock which previously was a “a Buy”.
Analyzing ARQT Stock Performance
On last trading session,, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 0.32% to $15.48. The stock’s lowest price that day was $15.17, but it reached a high of $15.575 in the same session. During the last five days, there has been a surge of approximately 1.38%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 43.73%.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
RSI (Relative Strength Index) is 61.91 on the 14-day chart, showing neutral technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 2.61 million shares to 18.64 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 16.04 million shares. A jump of 13.99% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.69 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.69.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 23.14% from the previous closing price of $15.43. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 19 by 2025, with the lowest price target being 19. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 13, 2023, Goldman assigned a price target of “a Neutral” to the stock and downgraded coverage with a $6.
